Lundbeck Cuts Its European Sales Teams By A Third, As It Builds Up Its Presence In the U.S. And Emerging Markets
This article was originally published in The Pink Sheet Daily
Lundbeck becomes the latest company in Europe to announce job cuts, as austerity, generic competition and unclear pricing and reimbursement practices create uncertainties.
You may also be interested in...
Denmark's CNS drugs specialist Lundbeck expects three 2013 product launches, a portfolio of new medicines and a marketing drive into markets outside anemic Europe to help offset lost revenue and profits caused by escitalopram patent expiry in the U.S. and Europe.
AstraZeneca is to slash 12% of its workforce in the next three years, as the company forecasts declining revenues in 2012 because of its steep patent cliff, government pricing interventions and R&D pipeline failures.
With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.